Answers are grounded in this paper and cite their sources.
In this phase III study, eribulin was not shown to be superior to capecitabine with regard to OS or PFS.
No takes yet. Share an insight, caveat, or question.
Kaufman et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: